About
Pipeline & Research
NEWS & MEDIA
Investors
Careers
Contact Us

Select Page

BeyondSpring Second-Quarter 2019 Financial Results and Operational Update

August 24, 2020

09.18.2019

BeyondSpring Second-Quarter 2019 Financial Results and Operational Update

Search for:

RECENT NEWS ARTICLES

BeyondSpring Announces Three Poster Presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting
BeyondSpring Files 2021 Annual Report on Form 20-F
BeyondSpring Announces Fourth Quarter and Year End 2021 Financial Results and Provides a Corporate Update
BeyondSpring to Announce Fourth Quarter and Year End 2021 Financial Results and Host a Conference Call on Thursday, April 14, 2022
BeyondSpring Announces Organizational Streamlining
BeyondSpring Announces Third Quarter 2021 Financial Results and Provides a Corporate Update
BeyondSpring Pharmaceuticals Announces New Clinical Data Confirming Plinabulin’s Fast Onset Mechanism of Action in the Prevention of Chemotherapy-Induced Neutropenia at the 63rd ASH Annual Meeting and Exposition
BeyondSpring Pharmaceuticals Announces Analysis of New Data on the Plinabulin/Pegfilgrastim Combination in Breast Cancer at the 2021 San Antonio Breast Cancer Symposium
BeyondSpring Pharmaceuticals Receives Complete Response Letter from the FDA for Plinabulin New Drug Application for Prevention of Chemotherapy-Induced Neutropenia (CIN)
BeyondSpring Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference

RECENT MEDIA COVERAGE

TD Ameritrade Watch List
Managing Chemotherapy Toxicities for Improved Patient Outcomes
New Treatment Modalities: Protein Degraders And Molecular Glues Gain Traction
Seed Therapeutics blossoms in an $800M deal with Lilly
Seed Therapeutics Launches Protein Degradation Research Platform and Appoints Edward Dongheng Liu as Chief Financial Officer
BeyondSpring Forms Partnership Advisory Committee Comprised of Industry Veterans
JAMA Oncology Highlights Plinabulin’s Efficacy in Preventing Chemotherapy-Induced Neutropenia as a Monotherapy
Pegfilgrastim Plus Plinabulin Reduces Chemo-Induced Neutropenia in TAC-Treated Patients
Dr. Lan Huang Featured in Nature Titled “‘Innovation’ Nation”
Woman of the Week Podcast: Dr. Lan Huang, Co-founder, Chairman and Chief Executive Officer BeyondSpring

WORK WITH US

LifeSci Advisors

Investor Contact
Ashley R. Robinson
+1 617-430-7577
arr@lifesciadvisors.com

Media Contact
Darren Opland, Ph.D.
+1 646-627-8387
darren@lifescicomms.com

BeyondSpring Inc.
+1 (646) 305-6387
general@beyondspringpharma.com

GET UPDATES

Subscribe to BeyondSpring News & Media!

Who We Are
Management Team
Scientific Advisors
Board of Directors

PIPELINE & RESEARCH

Pipeline Overview
Plinabulin
Protein Degradation
Other Pipeline
Posters & Publications
Collaboration
Expanded Access Policy

Stock Overview
Events & Presentations
Financials & Filings
Corporate Governance

Job Opportunities

NEWS & MEDIA

Press Releases
Media Coverage

BeyondSprings Inc LinkedIn

BeyondSprings Inc Twitter

©2021 BeyondSpring Inc. All rights reserved. Privacy Notice | Terms of Use

We use cookies to ensure that we give you the best experience on our website. Please click “OK” to continue or read our Privacy & Cookie Policy.Ok Privacy policy